ArticleWorld journal of surgical oncology2026
Survival benefit of local treatment for oligo-recurrence after esophageal cancer surgery.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative recurrence of esophageal cancer is generally associated with poor survival; however, oligo-recurrence, a limited pattern of recurrence, may influence long-term survival outcomes.
methodsWe retrospectively analyzed 57 patients who developed postoperative recurrence of thoracic esophageal cancer between April 2016 and March 2024. Oligo-recurrence was defined as recurrence involving three or fewer lesions confined to a single organ. Recurrence patterns, treatment strategies, and post-recurrence survival were evaluated.
resultsThe cohort included 48 men and 9 women, with a median age at recurrence of 72 years (range: 50–84 years). Oligo-recurrence occurred in 23 patients (40.4%); of these, 18 (78.3%) received local treatment (surgery or chemoradiotherapy), and 5 (21.7%) received chemotherapy alone. The 2-year post-recurrence survival rate was significantly higher in the oligo group than in the non-oligo group (50.8% vs. 3.7%, p < 0.05). Within the oligo group, 11 patients who achieved disease control with local treatment had a 2-year survival rate of 80%, compared with 13% in the remaining patients (p < 0.05). Univariate analysis identified early recurrence within 1 year (hazard ratio [HR]: 1.94; 95% confidence interval [CI]: 1.014–3.811; p < 0.05), oligo-recurrence (HR: 0.28; 95% CI: 0.143–0.555; p < 0.05), and local treatment (HR: 0.23; 95% CI: 0.107–0.525; p < 0.05) as significant factors. In multivariate analysis, only local treatment remained independently associated with improved survival (HR: 0.31; 95% CI: 0.087–0.998; p = 0.048).
conclusionsLocal treatment for oligo-recurrence is associated with improved survival outcomes in selected patients with recurrent esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.